

Douglas Galasko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9642497/publications.pdf>

Version: 2024-02-01

257
papers

50,419
citations

2963

93
h-index

1668

214
g-index

290
all docs

290
docs citations

290
times ranked

40780
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. <i>Brain</i> , 2011, 134, 2456-2477.	3.7	3,913
2	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	4.9	3,755
3	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
4	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	4.9	2,657
5	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
6	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. <i>New England Journal of Medicine</i> , 2005, 352, 2379-2388.	13.9	1,709
7	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 436-441.	9.4	1,676
8	The ageing systemic milieu negatively regulates neurogenesis and cognitive function. <i>Nature</i> , 2011, 477, 90-94.	13.7	1,453
9	Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. <i>Nature Medicine</i> , 2007, 13, 1359-1362.	15.2	969
10	An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease and Associated Disorders, 1997, 11, 33-39.	0.6	961
11	Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. <i>Lancet Neurology</i> , The, 2008, 7, 812-826.	4.9	960
12	Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials. <i>Archives of Neurology</i> , 2004, 61, 59.	4.9	853
13	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
14	The Alzheimer's Disease Centers' Uniform Data Set (UDS). <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 91-101.	0.6	684
15	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. <i>Lancet Neurology</i> , The, 2008, 7, 409-416.	4.9	636
16	DJ-1 and α -synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. <i>Brain</i> , 2010, 133, 713-726.	3.7	575
17	Secretion of β -amyloid precursor protein cleaved at the amino terminus of the β -amyloid peptide. <i>Nature</i> , 1993, 361, 260-263.	13.7	558
18	Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease. <i>Nature</i> , 2020, 577, 399-404.	13.7	537

#	ARTICLE	IF	CITATIONS
19	Rehabilitation of hemiparesis after stroke with a mirror. <i>Lancet, The</i> , 1999, 353, 2035-2036.	6.3	511
20	Plasma exosomal β -synuclein is likely CNS-derived and increased in Parkinson's disease. <i>Acta Neuropathologica</i> , 2014, 128, 639-650.	3.9	504
21	Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 275-289.	1.2	493
22	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , 2010, 42, 234-239.	9.4	479
23	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology, The</i> , 2011, 10, 484-496.	4.9	396
24	YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 903-912.	0.7	382
25	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. <i>Acta Neuropathologica</i> , 2007, 114, 221-229.	3.9	378
26	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. <i>Annals of Neurology</i> , 2011, 69, 570-580.	2.8	371
27	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. <i>Neuron</i> , 2013, 78, 256-268.	3.8	344
28	Cerebrospinal Fluid Tau and β -Amyloid. <i>Archives of Neurology</i> , 2003, 60, 1696.	4.9	341
29	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
30	Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of β -Synucleinopathy. <i>PLoS ONE</i> , 2010, 5, e9313.	1.1	327
31	Antioxidants for Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 836-41.	4.9	314
32	APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. <i>JAMA Neurology</i> , 2013, 70, 223.	4.5	302
33	Distinctive patterns of DNA methylation associated with Parkinson disease. <i>Epigenetics</i> , 2013, 8, 1030-1038.	1.3	275
34	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	4.1	260
35	Biological markers for therapeutic trials in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 521-536.	1.5	249
36	Rapid and ultra-sensitive quantitation of disease-associated β -synuclein seeds in brain and cerebrospinal fluid by β Syn RT-QuIC. <i>Acta Neuropathologica Communications</i> , 2018, 6, 7.	2.4	245

#	ARTICLE	IF	CITATIONS
37	Phosphorylated β -Synuclein in Parkinson's Disease. <i>Science Translational Medicine</i> , 2012, 4, 121ra20.	5.8	223
38	Amyloid- β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma. <i>Biochemical and Biophysical Research Communications</i> , 2000, 268, 750-756.	1.0	205
39	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 6-15.	0.6	203
40	Plaque-Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa. <i>Journal of Neuro pathology and Experimental Neurology</i> , 1993, 52, 648-654.	0.9	198
41	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. <i>Human Molecular Genetics</i> , 2012, 21, 3500-3512.	1.4	198
42	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
43	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
44	Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. <i>Alzheimer's and Dementia</i> , 2015, 11, 415-424.	0.4	194
45	Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. <i>Autophagy</i> , 2018, 14, 98-119.	4.3	193
46	Biomarkers of oxidative damage and inflammation in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2010, 4, 27-36.	0.6	191
47	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
48	Progressive accumulation of amyloid- β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. <i>FEBS Journal</i> , 2010, 277, 3051-3067.	2.2	188
49	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 480, 78-82.	1.0	184
50	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
51	Subjective Cognitive Complaints Contribute to Misdiagnosis of Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 836-847.	1.2	176
52	Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 794-802.	1.3	170
53	Safety and Acceptability of the Research Lumbar Puncture. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 220-225.	0.6	170
54	Neuropsychological Deficits Associated with Diffuse Lewy Body Disease. <i>Brain and Cognition</i> , 1996, 31, 148-165.	0.8	169

#	ARTICLE	IF	CITATIONS
55	Degree of bilingualism predicts age of diagnosis of Alzheimer's disease in low-education but not in highly educated Hispanics. <i>Neuropsychologia</i> , 2011, 49, 3826-3830.	0.7	169
56	Î±-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7813-7818.	3.3	168
57	The Spectrum of Mutations in Progranulin. <i>Archives of Neurology</i> , 2010, 67, 161-70.	4.9	166
58	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1394.	4.5	166
59	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1505-1521.	0.4	163
60	CSF AÎ²₄₂ and tau in Parkinson's disease with cognitive impairment. <i>Movement Disorders</i> , 2010, 25, 2682-2685.	2.2	162
61	Pathological TDP-43 in parkinsonismâ€“dementia complex and amyotrophic lateral sclerosis of Guam. <i>Acta Neuropathologica</i> , 2007, 115, 133-145.	3.9	161
62	Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex of Guam: Changing Incidence Rates during the Past 60 Years. <i>American Journal of Epidemiology</i> , 2003, 157, 149-157.	1.6	159
63	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. <i>Archives of Neurology</i> , 2010, 67, 1350-6.	4.9	157
64	The Î² ₂ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments. <i>Journal of Neurochemistry</i> , 1997, 68, 430-433.	2.1	154
65	ADCS Prevention Instrument Project: Assessment of Instrumental Activities of Daily Living for Community-dwelling Elderly Individuals in Dementia Prevention Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S152-S169.	0.6	153
66	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e16032.	1.1	152
67	Altered expression of the synuclein family mRNA in Lewy body and Alzheimerâ€™s disease. <i>Brain Research</i> , 2001, 914, 48-56.	1.1	150
68	Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 231-242.	1.2	147
69	Effects of Chronic Stress on Memory Decline in Cognitively Normal and Mildly Impaired Older Adults. <i>American Journal of Psychiatry</i> , 2009, 166, 1384-1391.	4.0	145
70	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. <i>Archives of Neurology</i> , 2001, 58, 383-7.	4.9	143
71	Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease.. <i>Neuropsychology</i> , 2007, 21, 20-30.	1.0	143
72	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	2.2	136

#	ARTICLE	IF	CITATIONS
73	Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2005, 11, 446-453.	1.2	135
74	PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 206-212.	0.6	134
75	Preclinical cognitive markers of dementia of the Alzheimer type.. <i>Neuropsychology</i> , 1994, 8, 374-384.	1.0	127
76	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	3.9	123
77	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	3.7	122
78	Neocortical Lewy Body Counts Correlate with Dementia in the Lewy Body Variant of Alzheimer's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 44-52.	0.9	120
79	Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients. <i>Cell Stem Cell</i> , 2021, 28, 1533-1548.e6.	5.2	119
80	Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid β -Amyloid 42 in Adults With Normal Cognition. <i>Archives of Neurology</i> , 2006, 63, 936.	4.9	118
81	Incidence of New-Onset Seizures in Mild to Moderate Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 368.	4.9	117
82	Alzheimer's disease: The right drug, the right time. <i>Science</i> , 2018, 362, 1250-1251.	6.0	114
83	Decline in verbal memory during preclinical Alzheimer's disease: Examination of the effect of APOE genotype. <i>Journal of the International Neuropsychological Society</i> , 2002, 8, 943-955.	1.2	113
84	Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects. <i>PLoS ONE</i> , 2009, 4, e5424.	1.1	112
85	Cognitive Profiles of Autopsy-Confirmed Lewy Body Variant vs Pure Alzheimer Disease. <i>Archives of Neurology</i> , 1998, 55, 994.	4.9	111
86	Safety, Tolerability, Pharmacokinetics, and $A\beta$ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, 292-299.	0.6	111
87	SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease. <i>PLoS Genetics</i> , 2010, 6, e1001101.	1.5	111
88	A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. <i>Oncotarget</i> , 2017, 8, 68769-68779.	0.8	111
89	RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy-Related Pathology in the Dementia Patient. <i>Brain Pathology</i> , 2008, 18, 220-224.	2.1	106
90	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104

#	ARTICLE	IF	CITATIONS
91	Longitudinal stability of CSF tau levels in Alzheimer patients. <i>Biological Psychiatry</i> , 1999, 46, 750-755.	0.7	103
92	Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease. <i>Movement Disorders</i> , 2006, 21, 337-342.	2.2	103
93	Pulse Pressure in Relation to Tau-Mediated Neurodegeneration, Cerebral Amyloidosis, and Progression to Dementia in Very Old Adults. <i>JAMA Neurology</i> , 2015, 72, 546.	4.5	101
94	Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> , 2006, 10, 399-406.	1.2	97
95	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. <i>American Journal of Pathology</i> , 2011, 178, 1509-1516.	1.9	97
96	Effect of Knowledge of APOE Genotype on Subjective and Objective Memory Performance in Healthy Older Adults. <i>American Journal of Psychiatry</i> , 2014, 171, 201-208.	4.0	97
97	Monitoring Progression in Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1991, 39, 932-941.	1.3	94
98	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020, 19, 71-80.	4.9	94
99	Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. <i>Neurobiology of Aging</i> , 2011, 32, 2113-2122.	1.5	93
100	Hippocampal β -Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. <i>Journal of Neuroscience</i> , 2017, 37, 1675-1684.	1.7	92
101	CD4 ⁺ T cells contribute to neurodegeneration in Lewy body dementia. <i>Science</i> , 2021, 374, 868-874.	6.0	92
102	Preclinical Evidence of Alzheimer Changes. <i>Archives of Neurology</i> , 2009, 66, 632-7.	4.9	89
103	Longitudinal analyses of cerebrospinal fluid β -Synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1354-1364.	2.2	89
104	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2020, 139, 63-77.	3.9	89
105	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. <i>Acta Neuropathologica</i> , 2022, 143, 487-503.	3.9	89
106	The Effects of Prolonged Stress and APOE Genotype on Memory and Cortisol in Older Adults. <i>Biological Psychiatry</i> , 2007, 62, 472-478.	0.7	87
107	Early versus late MCI: Improved MCI staging using a neuropsychological approach. <i>Alzheimer's and Dementia</i> , 2019, 15, 699-708.	0.4	84
108	Diagnosing Depression in Alzheimer Disease With the National Institute of Mental Health Provisional Criteria. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 469-477.	0.6	82

#	ARTICLE	IF	CITATIONS
109	A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2004, 10, 689-697.	1.2	81
110	Measuring cognitive change in a cohort of patients with Alzheimer's disease. , 2000, 19, 1421-1432.		80
111	Extrapyramidal Motor Signs in Clinically Diagnosed Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1996, 10, 103-114.	0.6	79
112	Reduction of SorLA/LR11, a Sorting Protein Limiting β -Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid. <i>Archives of Neurology</i> , 2009, 66, 448-57.	4.9	79
113	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , 2018, 141, 1486-1500.	3.7	79
114	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 871-882.	1.8	79
115	Stimulated platelets release amyloid β -protein precursor. <i>Biochemical and Biophysical Research Communications</i> , 1990, 170, 288-295.	1.0	78
116	Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease.. <i>Neuropsychology</i> , 2007, 21, 696-705.	1.0	77
117	Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. <i>International Journal of Psychophysiology</i> , 2003, 47, 95-115.	0.5	76
118	Multiple SNPs Within and Surrounding the Apolipoprotein E Gene Influence Cerebrospinal Fluid Apolipoprotein E Protein Levels. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 255-266.	1.2	75
119	The Influence of Chronic Stress on Dementia-related Diagnostic Change in Older Adults. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 260-266.	0.6	75
120	Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.. <i>Neuropsychology</i> , 2008, 22, 729-737.	1.0	72
121	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 226-235.	1.7	72
122	Widespread microRNA dysregulation in multiple system atrophy " disease-related alteration in miR-96. <i>European Journal of Neuroscience</i> , 2014, 39, 1026-1041.	1.2	68
123	Analysis of extracellular RNA in cerebrospinal fluid. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1317577.	5.5	68
124	Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. <i>Journal of Proteome Research</i> , 2008, 7, 720-730.	1.8	67
125	Clinical Features Distinguishing Large Cohorts with Possible AD, Probable AD, and Mixed Dementia. <i>Journal of the American Geriatrics Society</i> , 1993, 41, 31-37.	1.3	66
126	Biomarkers for Alzheimer's disease " Clinical needs and application. <i>Journal of Alzheimer's Disease</i> , 2006, 8, 339-346.	1.2	66

#	ARTICLE	IF	CITATIONS
127	Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer's Disease as Identified by Biomarkers. <i>NeuroMolecular Medicine</i> , 2011, 13, 37-43.	1.8	65
128	Missed Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 685-691.	1.2	63
129	Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 1825-1828.	0.6	60
130	Galantamine Maintains Ability to Perform Activities of Daily Living in Patients with Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1070-1076.	1.3	60
131	ADCS Prevention Instrument Project: Overview and Initial Results. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S109-S123.	0.6	60
132	Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. <i>Human Molecular Genetics</i> , 2007, 16, 295-306.	1.4	59
133	Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 842-853.	1.2	58
134	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622.	2.2	55
135	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020, 88, 574-587.	2.8	55
136	A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017, 32, 1117-1130.	2.2	54
137	An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour. <i>European Journal of Neurology</i> , 1998, 5, S9.	1.7	52
138	Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 544-555.	2.5	51
139	Lewy Body Disorders. <i>Neurologic Clinics</i> , 2017, 35, 325-338.	0.8	51
140	Lewy Body Dementia – Diagnosis and Treatment. <i>British Journal of Psychiatry</i> , 1995, 167, 709-717.	1.7	50
141	Sex differences in Alzheimer's-related Tau biomarkers and a mediating effect of testosterone. <i>Biology of Sex Differences</i> , 2020, 11, 33.	1.8	50
142	Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 72-78.	1.1	49
143	Death Certificate Reporting of Dementia and Mortality in an Alzheimer's Disease Research Center Cohort. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 890-893.	1.3	48
144	Primary brain calcification: an international study reporting novel variants and associated phenotypes. <i>European Journal of Human Genetics</i> , 2018, 26, 1462-1477.	1.4	48

#	ARTICLE	IF	CITATIONS
145	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	2.2	48
146	Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 373-383.	1.2	46
147	Apolipoprotein-E ϵ 4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. <i>Neuroscience Letters</i> , 1994, 182, 63-65.	1.0	45
148	Early Visuospatial Deficits Predict the Occurrence of Visual Hallucinations in Autopsy-Confirmed Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 773-781.	0.6	45
149	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45
150	Dedifferentiation and neuronal repression define familial Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	4.7	44
151	Antemortem Pulse Pressure Elevation Predicts Cerebrovascular Disease in Autopsy-Confirmed Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 595-603.	1.2	43
152	Subjective Cognitive Decline, Objective Cognition, and Depression in Older Hispanics Screened for Memory Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 949-956.	1.2	43
153	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e2076-e2087.	1.5	42
154	Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States. <i>JAMA Neurology</i> , 2015, 72, 209.	4.5	41
155	Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 875-891.	1.2	41
156	Early-onset Alzheimer's disease with a presenilin-1 mutation at the site corresponding to the volga German presenilin-2 mutation. <i>Annals of Neurology</i> , 1997, 42, 124-128.	2.8	40
157	Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 819-823.	1.3	40
158	Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span. <i>JAMA Neurology</i> , 2014, 71, 742.	4.5	40
159	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α -Synuclein in PDGBA. <i>Movement Disorders</i> , 2021, 36, 1216-1228.	2.2	40
160	A rapid α -Synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 374-384.	1.7	40
161	Preclinical validation of a potent β -secretase modulator for Alzheimer's disease prevention. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	39
162	Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. <i>Human Molecular Genetics</i> , 2009, 18, 3725-3738.	1.4	37

#	ARTICLE	IF	CITATIONS
163	Dopamine transporter imaging predicts clinically defined α -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212.	1.7	37
164	Reduced hypocretin (orexin) levels in dementia with Lewy bodies. <i>NeuroReport</i> , 2010, 21, 756-760.	0.6	35
165	Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. <i>Neuroscience Letters</i> , 1998, 254, 1-4.	1.0	34
166	Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. <i>Toxicology and Applied Pharmacology</i> , 2009, 240, 180-188.	1.3	33
167	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 672-687.	0.9	33
168	Intracellular $A\beta$ is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines. <i>Neurobiology of Aging</i> , 2002, 23, 195-203.	1.5	31
169	Performance of α -Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	31
170	Targeted Discovery and Validation of Plasma Biomarkers of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2014, 13, 4535-4545.	1.8	30
171	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid $A\beta$ 1-42 in CSF for the Diagnosis of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2017, 16, 1228-1238.	1.8	30
172	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	3.7	30
173	Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer's disease. <i>Cognitive Neuroscience</i> , 2013, 4, 143-151.	0.6	29
174	A Longitudinal Study of Total and Phosphorylated α -Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1541-1553.	1.2	29
175	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
176	Effect of Extrapyramidal Signs and Lewy Bodies on Survival in Patients With Alzheimer Disease. <i>Archives of Neurology</i> , 2002, 59, 588.	4.9	28
177	The New Qualitative Scoring MMSE Pentagon Test (QSPT) as a Valid Screening Tool between Autopsy-Confirmed Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 823-832.	1.2	28
178	Diagnostic Values of Cerebrospinal Fluid T-Tau and $A\beta$ 1-42 using Meso Scale Discovery Assays for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 709-719.	1.2	28
179	Quantifying Drug-Induced Changes in Parkinsonian Rigidity Using an Instrumental Measure of Activated Stiffness. <i>Clinical Neuropharmacology</i> , 1992, 15, 1-12.	0.2	27
180	Cerebrospinal Fluid α -Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1007-1016.	1.2	27

#	ARTICLE	IF	CITATIONS
181	Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex. <i>Acta Neuropathologica</i> , 2006, 111, 401-412.	3.9	26
182	CSF biomarkers for Alzheimer disease " approaching consensus. <i>Nature Reviews Neurology</i> , 2017, 13, 131-132.	4.9	26
183	Microstructural brain changes track cognitive decline in mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2018, 20, 883-891.	1.4	26
184	Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson's disease progression. <i>Nature Aging</i> , 2021, 1, 309-322.	5.3	26
185	Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. <i>Neurobiology of Aging</i> , 2013, 34, 2287-2292.	1.5	25
186	Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 55.	3.0	25
187	Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 561-569.	0.4	25
188	Role of LRP in TGF β 2-mediated neuronal uptake of A β and effects on memory. <i>Journal of Neuroscience Research</i> , 2004, 77, 217-228.	1.3	23
189	Quantitative Proteomics Identifies Surfactant-Resistant β -Synuclein in Cerebral Cortex of Parkinsonism-Dementia Complex of Guam but Not Alzheimer's Disease or Progressive Supranuclear Palsy. <i>American Journal of Pathology</i> , 2007, 171, 993-1002.	1.9	23
190	Influence of Lifestyle Modifications on Age-Related Free Radical Injury to Brain. <i>JAMA Neurology</i> , 2014, 71, 1150.	4.5	23
191	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	1.7	23
192	New approaches to diagnose and treat alzheimer's disease. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 393-410.	1.0	22
193	Potential Use of β -Secretase Modulators in the Treatment of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1255.	4.9	22
194	C9orf72 Hexanucleotide Repeat Expansion and Guam Amyotrophic Lateral Sclerosis " Parkinsonism-Dementia Complex. <i>JAMA Neurology</i> , 2013, 70, 742.	4.5	22
195	Neuropsychiatric Features of Frontal Lobe Dysfunction in Autopsy-Confirmed Patients with Lewy Bodies and "Pure" Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 509-519.	0.6	22
196	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2015, 11, 1069-1079.	0.4	22
197	Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnesic MCI and AD dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 763-768.	1.3	22
198	Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively defined subtle cognitive decline and MCI. <i>Alzheimer's and Dementia</i> , 2021, 17, 1756-1762.	0.4	22

#	ARTICLE	IF	CITATIONS
199	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. PLoS ONE, 2021, 16, e0257372.	1.1	22
200	Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 823-834.	0.8	21
201	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
202	Adjunctive Therapy in Patients with Alzheimer's Disease. Drugs and Aging, 1995, 7, 79-87.	1.3	20
203	No Long-Term Effect of Behavioral Treatment on Psychotropic Drug Use for Agitation in Alzheimer's Disease Patients. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 95-98.	1.2	20
204	Neuropathology of dementia with Lewy bodies in advanced age: A comparison with Alzheimer disease. Neuroscience Letters, 2010, 485, 222-227.	1.0	20
205	Cerebrospinal Fluid Opens a Window on Alzheimer Disease. Archives of Neurology, 1999, 56, 655.	4.9	19
206	Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. Alzheimer's and Dementia, 2016, 12, 75-84.	0.4	19
207	Detection of Peri-Synaptic Amyloid- β Pyroglutamate Aggregates in Early Stages of Alzheimer's Disease and in A β 2PP Transgenic Mice Using a Novel Monoclonal Antibody. Journal of Alzheimer's Disease, 2012, 28, 783-794.	1.2	18
208	Improved Statistical Power of Alzheimer Clinical Trials by Item-Response Theory. Alzheimer Disease and Associated Disorders, 2013, 27, 187-191.	0.6	18
209	Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: Beyond cognition. , 2014, 10, 171-178.		18
210	Sex Influences the Accuracy of Subjective Memory Complaint Reporting in Older Adults. Journal of Alzheimer's Disease, 2018, 61, 1163-1178.	1.2	18
211	A fibroblast growth factor binding protein in human cerebral spinal fluid. NeuroReport, 1995, 6, 886-888.	0.6	17
212	Biological Markers and the Treatment of Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 119-225.	1.1	17
213	Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 925-935.	0.8	17
214	Effects of Baseline CSF β -Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2013, 8, e85443.	1.1	16
215	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Frontiers in Neurology, 2015, 6, 256.	1.1	16
216	Visual search in Dementia with Lewy Bodies and Alzheimer's disease. Cortex, 2015, 73, 228-239.	1.1	16

#	ARTICLE	IF	CITATIONS
217	Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF A β 42 and Tau. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 883-887.	1.2	15
218	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinson's Disease</i> , 2019, 9, 665-679.	1.5	15
219	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
220	Associations Between Microstructure, Amyloid, and Cognition in Amnesic Mild Cognitive Impairment and Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 347-357.	1.2	15
221	Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. <i>Neurology</i> , 2021, 96, e2272-e2283.	1.5	15
222	Extrapyramidal signs and cognitive abilities in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 907-911.	1.3	14
223	Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 609-619.	1.2	14
224	Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 291-302.	1.2	14
225	Lewy bodies and dementia. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 435-441.	2.0	13
226	Cerebrospinal Fluid Biomarkers in Alzheimer Disease. <i>Archives of Neurology</i> , 2003, 60, 1195-6.	4.9	13
227	Brain Structure and Cerebrovascular Risk in Cognitively Impaired Patients. <i>Archives of Neurology</i> , 2010, 67, 1231-7.	4.9	13
228	Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 75, 169-177.	1.5	13
229	Distinct structural correlates of the dominant and nondominant languages in bilinguals with Alzheimer's disease (AD). <i>Neuropsychologia</i> , 2019, 132, 107131.	0.7	12
230	Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12118.	1.2	12
231	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. <i>Cortex</i> , 2021, 139, 99-115.	1.1	12
232	Data-Driven vs Consensus Diagnosis of MCI. <i>Neurology</i> , 2021, 97, e1288-e1299.	1.5	12
233	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135.	1.1	12
234	Apolipoprotein E Highly Correlates with A β PP- and Tau-Related Markers in Human Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 409-417.	1.2	11

#	ARTICLE	IF	CITATIONS
235	Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1539-1548.	1.2	11
236	LRP10 in β -synucleinopathies. <i>Lancet Neurology</i> , The, 2018, 17, 1032-1033.	4.9	11
237	Modulation of $A\beta_{42}$ in vivo by β -secretase modulator in primates and humans. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 55.	3.0	9
238	Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 2117-2130.	0.4	9
239	Prostaglandin E2 Induced Polymerization of Human β -1-Antichymotrypsin and Suppressed Its Protease Inhibitory Activity: Implications for Alzheimer's Disease. <i>Biochemical and Biophysical Research Communications</i> , 1998, 249, 182-186.	1.0	8
240	Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam. <i>NeuroReport</i> , 2001, 12, 3901-3903.	0.6	8
241	Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease. <i>Neuropsychologia</i> , 2015, 75, 548-555.	0.7	8
242	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 27-31.	1.2	8
243	Temporal Sequence Learning in Healthy Aging and Amnesic Mild Cognitive Impairment. <i>Experimental Aging Research</i> , 2013, 39, 371-381.	0.6	7
244	Failure to stop autocorrect errors in reading aloud increases in aging especially with a positive biomarker for Alzheimer's disease. <i>Psychology and Aging</i> , 2020, 35, 1016-1025.	1.4	7
245	The Clinical Spectrum of Guam ALS and Parkinson-Dementia Complex: 1997-1999. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 120-125.	1.8	6
246	Fractional synthesis and clearance rates for amyloid β . <i>Nature Medicine</i> , 2011, 17, 1178-1179.	15.2	6
247	Dynamics of neuroinflammation in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2022, 21, 297-298.	4.9	6
248	The Diagnostic Evaluation of a Patient With Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 397-410.	0.4	5
249	Biomarkers in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 375-381.	0.8	3
250	A Case of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FET) With Corticobasal Features and Language Deficits. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 890-892.	0.9	3
251	Encouraging trends toward reduced risk of Alzheimer disease. <i>Neurology: Clinical Practice</i> , 2015, 5, 190-192.	0.8	2
252	DEMENTIA WITH LEWY BODIES. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2007, 13, 69-86.	0.4	1

#	ARTICLE	IF	CITATIONS
253	Active immunization in Alzheimer's disease. <i>Nature Aging</i> , 2021, 1, 493-495.	5.3	1
254	The memory disorders clinic. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 107-112.	1.0	0
255	Recent Alzheimer's disease research highlights. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 14.	3.0	0
256	[O4]: NEURONAL PENTRAXIN 2 (NPTX2): A SYNAPTIC BIOMARKER OF COGNITIVE DYSFUNCTION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1231.	0.4	0
257	Alzheimer's disease and the processing of uncertainty during choice task performance: Executive dysfunction within the Hick-Hyman law. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 380-389.	0.8	0